To innovate with the great impact, we will focus on our 3 therapeutic areas - oncology, gastroenterology (GI), and central nervous system (CNS) disease areas. Moreover, we intend to continue to build upon our global health approach to Vaccines.
We are committed to being a global player in CNS, expanding in psychiatry and creating an anchor in neurology through partnership and co-development. Our focus is on patients with neuropsychiatric disorders who have no adequate available treatments for schizophrenia, depression and selected neurological diseases.
Patients with gastrointestinal (GI) disease often are affected when they are young and otherwise healthy, busy with family and careers. As a long-time leader in this therapeutic area, we are continually seeking new ways to help them return to health, and allow them to continue with their active lives.
Our aspiration is to be a top 10 oncology company in 2025 and rank top 5 in hematological malignancies. By delivering more effective treatments for cancer, we potentially can transform the outlook for millions of people around the world.
Please also visit our Takeda Oncology site.
Vaccines save millions of lives each year and are among the most cost-effective health interventions ever developed. By taking a global view, we are leveraging world-class capabilities to address intractable population health issues. We are working to develop vaccine candidates against dengue virus and norovirus.